Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Essen Biotech
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06640582CT.gov TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas | — | Recruiting | — | — | — |
NCT05521984CT.gov Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) | — | Recruiting | — | — | — |
NCT05317858CT.gov Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets | — | Recruiting | — | — | — |
NCT04479241CT.gov LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma | — | Completed | — | — | — |
NCT04239092CT.gov 9-ING-41 in Pediatric Patients With Refractory Malignancies. | — | Terminated | — | — | — |
NCT03426891CT.gov Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma | — | Completed | — | — | — |
NCT03152318CT.gov A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 | — | Active Not Recruiting | — | — | — |
NCT02798406CT.gov Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects | — | Completed | — | — | — |
NCT02389309CT.gov Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT02359565CT.gov Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma | — | Active Not Recruiting | — | — | — |
Show 5 more trialsShow fewer
NCT02186509CT.gov Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas | — | Completed | — | — | — |
NCT01875601CT.gov NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00641706CT.gov Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme | — | Completed | — | — | — |
NCT00078988CT.gov High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas | — | Completed | — | — | — |
NCT00003141CT.gov Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Brain Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclophosphamide (this asset) | Essen Biotech | P3 | BB · 67 |
| Cediranib | M.D. Anderson Cancer Center | P2 | BBB |
| Temsirolimus | M.D. Anderson Cancer Center | P2 | BBB |
| Sorafenib | National Cancer Institute (NCI) | P2 | BB |
| Dexmedetomidine | Kaohsiung Medical University Chung-Ho Memorial Hospital | P4 | BB |
| Vorinostat | H. Lee Moffitt Cancer Center and Research Institute | P2 | BB |
| Nivolumab | InSightec | P3 | BB |
| Nogitecan | Jeffrey N. Bruce | P2 | BB |
| Irinotecan | NaviFUS Corporation | P3 | BB |
+41 more in the Brain Neoplasm cohort
Other indications for Cyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Mycosis Fungoides | — | P4 | BBB · 78 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cyclophosphamide in Brain Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cyclophosphamide-brain-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →